April 2012
- LRG mourns the loss of a great friend, Jeroen Pit
- GDOL Update: Speakers announced
- LRG Research Team meets in Leuven, Belgium: leaves with renewed energy & commitment to finding the cure for GIST
- Meet our new Montana local rep: Dirk Niebaum
- Cellular origin of GIST from the “good” cells’ perspective
- Alianza GIST meets in Miami
- And they’re off! 1st ‘Harness a Cure’ is a success
- NJ GIST gathering serves up support & smoothies
- NoCal GISTers meet!
- New report finds most hospital errors go unreported
- Happy Cancerversary to Brenda Bannon!
- Thomas G. Overley, 1952-2012: Toledo lawyer played guitar, sang in group
- Durham lived life with passion and pride
- Did You Hear? Did You Know?
- Arizona GISTers meet!
- Spunky Texan fought GIST bravely
- Calendar
Article List
February 2012
Did You Know?
AROG
In April 2011, AROG Pharmaceuticals initiated a phase II trial of crenolanib (CP-868,596) for GIST patients with PDGFRA-D842V mutation. The current status of the trial was presented at CTOS 2011, and includes data regarding a metabolic response that was observed in a patient. The trial is currently ongoing at Fox Chase Cancer Center (Principal Investigator (PI): Dr. Margaret von-Mehren) and Oregon Health Sciences University (PI: Dr. Michael Heinrich). To ensure that crenolanib is not given to the patients at a sub-optimal dose, AROG has escalated the current dose by approximately 1.7 fold. Also, in an effort to provide therapeutic benefit to a maximum number of patients, AROG has increased the sample size and also allowed the patients that had discontinued from the study to re-enroll in the study at the higher dose.
Currently available drugs like imatinib and sunitinib have no activity against the PDGFRA-D842V mutated GIST. AROG is hopeful that crenolanib will help provide therapeutic benefits to these patients that currently have no treatment.
0 Comments